Gregory B. Lesinski

8.2k total citations · 2 hit papers
174 papers, 5.8k citations indexed

About

Gregory B. Lesinski is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gregory B. Lesinski has authored 174 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 68 papers in Immunology and 58 papers in Molecular Biology. Recurrent topics in Gregory B. Lesinski's work include Cancer Immunotherapy and Biomarkers (41 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Cytokine Signaling Pathways and Interactions (24 papers). Gregory B. Lesinski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (41 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Cytokine Signaling Pathways and Interactions (24 papers). Gregory B. Lesinski collaborates with scholars based in United States, China and Thailand. Gregory B. Lesinski's co-authors include Gregory Young, Thomas A. Mace, William E. Carson, Bassel F. El‐Rayes, Tanios Bekaii‐Saab, Mark Bloomston, M.A. Julie Westerink, Christina Wu, James R. Fuchs and Mehmet Akce and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Gregory B. Lesinski

166 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

2016 401 citations Thomas A. Mace, Reena Shakya et al. profile →
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms

2019 263 citations Gregory B. Lesinski, Bassel F. El‐Rayes et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Gregory B. Lesinski	3.0k	2.1k	2.0k	724	482	174	5.8k
Said Dermime	2.6k 0.9×	2.2k 1.1×	1.9k 0.9×	596 0.8×	249 0.5×	101	5.6k
Cédric Rébé	2.5k 0.8×	3.3k 1.6×	2.8k 1.4×	734 1.0×	515 1.1×	70	6.7k
Alice Mui	2.6k 0.9×	3.0k 1.5×	2.6k 1.3×	747 1.0×	362 0.8×	92	6.5k
Florencia McAllister	3.3k 1.1×	2.3k 1.1×	2.5k 1.2×	1.2k 1.6×	754 1.6×	89	6.7k
Shoichi Hazama	2.1k 0.7×	1.2k 0.6×	1.7k 0.8×	725 1.0×	668 1.4×	187	4.5k
Roberto Benelli	2.0k 0.7×	1.7k 0.8×	2.6k 1.2×	1.1k 1.5×	467 1.0×	123	6.7k
Sandra E. Nicholson	3.5k 1.2×	3.4k 1.7×	2.4k 1.2×	816 1.1×	245 0.5×	90	6.7k
Michael B. Dwinell	2.0k 0.7×	1.8k 0.9×	1.8k 0.9×	726 1.0×	367 0.8×	85	4.8k
Yiwei Chu	2.4k 0.8×	3.6k 1.8×	2.9k 1.4×	1.3k 1.8×	370 0.8×	182	7.7k
Johannes Stöckl	1.5k 0.5×	2.9k 1.4×	2.0k 1.0×	496 0.7×	393 0.8×	93	5.9k

Countries citing papers authored by Gregory B. Lesinski

Since Specialization

Citations

This map shows the geographic impact of Gregory B. Lesinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory B. Lesinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory B. Lesinski more than expected).

Fields of papers citing papers by Gregory B. Lesinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory B. Lesinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory B. Lesinski. The network helps show where Gregory B. Lesinski may publish in the future.

Co-authorship network of co-authors of Gregory B. Lesinski

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory B. Lesinski. A scholar is included among the top collaborators of Gregory B. Lesinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory B. Lesinski. Gregory B. Lesinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bailey, Stefanie R., Eric Bartee, Kyle G. Daniels, et al.. (2025). Constructing the cure: engineering the next wave of antibody and cellular immune therapies. Journal for ImmunoTherapy of Cancer. 13(8). e011761–e011761.

Heumann, Thatcher, Mark Yarchoan, Jiayun Lu, et al.. (2024). A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4017–4017. 3 indexed citations

Zhang, Hanwen, et al.. (2024). VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. Cancer Research. 84(18). 2954–2967. 4 indexed citations

Yarchoan, Mark, Subir Goyal, Yuan Liu, et al.. (2022). Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical Cancer Research. 28(19). 4336–4345. 10 indexed citations

Han, Samuel, Darwin L. Conwell, Liang Li, et al.. (2022). The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial. Pancreatology. 23(1). 42–47. 7 indexed citations

Dennison, Lauren, Aditya Mohan, James M. Leatherman, et al.. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. 9(10). 1187–1201. 17 indexed citations

Zaidi, Mohammad Y., Brian M. Olson, Matthew R. Farren, et al.. (2020). Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics. 20(1). 150–160. 39 indexed citations

Świdnicka‐Siergiejko, Agnieszka, Myrriah Chavez-Tomar, Gregory B. Lesinski, et al.. (2017). Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Research. 77(10). 2647–2660. 114 indexed citations

Farren, Matthew R., Reena Shakya, Gregory Young, et al.. (2017). The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Molecular Cancer Therapeutics. 16(3). 417–427. 23 indexed citations

10.

Talbert, Erin E., Jennifer Yang, Thomas A. Mace, et al.. (2016). Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Molecular Cancer Therapeutics. 16(2). 344–356. 29 indexed citations

11.

Lesinski, Gregory B., Patrick K. Reville, Thomas A. Mace, et al.. (2015). Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prevention Research. 8(11). 1036–1044. 70 indexed citations

12.

Farren, Matthew R., Thomas A. Mace, Susan Geyer, et al.. (2015). Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research. 22(10). 2565–2574. 69 indexed citations

13.

Ahn‐Jarvis, Jennifer, Steven K. Clinton, Elizabeth M. Grainger, et al.. (2015). Isoflavone Pharmacokinetics and Metabolism after Consumption of a Standardized Soy and Soy–Almond Bread in Men with Asymptomatic Prostate Cancer. Cancer Prevention Research. 8(11). 1045–1054. 29 indexed citations

14.

Sborov, Douglas W., Gerard J. Nuovo, Andrew Stiff, et al.. (2014). A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. Clinical Cancer Research. 20(23). 5946–5955. 71 indexed citations

15.

Mace, Thomas A., Zeenath Ameen, Amy Collins, et al.. (2013). Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner. Cancer Research. 73(10). 3007–3018. 344 indexed citations

16.

Mundy-Bosse, Bethany L., Gregory B. Lesinski, Alena Cristina Jaime‐Ramirez, et al.. (2011). Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice. Cancer Research. 71(15). 5101–5110. 149 indexed citations

17.

Zimmerer, Jason M., Gregory B. Lesinski, Amy S. Ruppert, et al.. (2008). Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α. Clinical Cancer Research. 14(18). 5900–5906. 27 indexed citations

18.

Lesinski, Gregory B., Kristan Guenterberg, Michael R. Go, et al.. (2008). IFN-α and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Research. 68(20). 8351–8360. 44 indexed citations

19.

Lesinski, Gregory B., John C. Trefry, Sri Vidya Kondadasula, et al.. (2007). Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-α Compared with Immune Effector Cells. Clinical Cancer Research. 13(17). 5010–5019. 30 indexed citations

20.

Lesinski, Gregory B., Mirela Anghelina, Jason M. Zimmerer, et al.. (2003). The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. Journal of Clinical Investigation. 112(2). 170–180. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact